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Abstract
Inflammation caused by oxidative stress (ROS) is a main driver for development of 
chronic inflammatory liver disease leading to fibrosis and cirrhosis. An important source 
of ROS constitutes methylglyoxal (MGO). MGO is formed as a by-product in glycoly-
sis, threonine catabolism, and ketone bodies pathway leading to formation of advanced 
glycation end products (AGEs). AGEs bind to their receptor for AGEs (RAGE) and acti-
vate intracellular transcription factors, such as nuclear factor-κB (NF-κB), resulting in 
production of pro-inflammatory cytokines and ROS. The enzymes glyoxalase-I (Glo-I) 
and glyoxalase-II (Glo-II) form the glyoxalase system and are essential for the detoxi-
fication of methylglyoxal (MGO). This chapter highlights Glo-I and (R)AGE in chronic 
liver disease with focus on fibrosis and cirrhosis. AGEs and RAGE have been shown to 
be upregulated in fibrosis, and silencing of RAGE reduced the latter. In contrast, recent 
study highlighted reduced expression of Glo-I in cirrhosis with consecutive elevation of 
MGO and oxidative stress. Interestingly, modulation of Glo-I activity by ethyl pyruvate 
resulted in reduced activation of hepatic stellate cells and reduced fibrosis in CCl
4
 model 
of cirrhosis. In conclusion, Glo-I and R(AGE) are important components in development 
and progression of chronic liver disease and constitute interesting therapeutic target.
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1. Introduction
Oxidate stress (reactive oxygen species, ROS) with consecutive and repetitive inflammation 
is responsible for development of chronic liver disease. Different etiologies of liver disease 
lead to damage of hepatocytes, release of pro-inflammatory cytokines, and finally activation 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
of hepatic stellate cells (HSC). Activated HSC transform to myofibroblasts and lead to deposi-
tion of collagen, which in turn result in fibrosis and finally cirrhosis. Several molecular mecha-
nisms are involved in this complex interplay, nevertheless the critical step is the activation of 
HSC by ROS. This chapter focuses on the glyoxalase-I (Glo-I) and related advanced glycation 
end products (AGEs) with their receptor for AGEs (RAGE) playing an important role in gen-
eration and detoxification of ROS. Current knowledge of Glo-I and (R)AGE in chronic liver 
disease with key aspect to fibrosis and cirrhosis will be highlighted.
2. Pathogenesis of fibrosis and cirrhosis
End-stage liver diseases are mainly caused by viral hepatitis, alcoholism, nonalcoholic fatty 
liver disease or steatohepatitis (NAFLD/NASH), or rare autoimmune and hereditary disor-
ders. The followed repetitive liver injury caused inflammation, finally resulting in fibrosis and 
irreversible cirrhosis. Thereby, liver cirrhosis belongs to the global burden of disease respon-
sible for more than one million deaths p.a. [1]. In cirrhosis, altered liver anatomy and reduced 
liver function are pathognomonic. Development of cirrhosis is characterized by the appear-
ance of regenerative nodules, hepatocyte ballooning, accumulation of fibrotic tissue, disturbed 
microcirculation, angiogenesis and sinusoidal collapse with defenestration and development 
of a basement membrane [2]. These alterations of liver architecture lead to reduced liver func-
tion and elevation of intrahepatic resistance demonstrated by increased portal pressure with 
development of ascites and esophageal varices [3, 4]. Nevertheless, portal hypertension is 
being caused by both structural alterations of liver microarchitecture and hepatic endothelial 
dysfunction. The latter is characterized by an imbalance of vasoactive components. In fact, 
there is an hyperresponsiveness and overproduction of vasoconstrictors (mainly endothelin-1 
(ET-1)) and an hyporesponsiveness and reduction of vasodilators (mainly nitric oxide (NO)) 
in the vascular bed of the liver [5–7]. Despite this hypoactive endothelium in hepatic micro-
circulation, portal hypertension leads to arterial vasodilation, formation of collateral vessels, 
and hyporesponsiveness to vasoconstrictors due to hyperactive endothelium in splanchnic 
and systemic circulation with increased NO production. Finally, these alterations result in 
elevated blood flow to portal vein and a vicious circle of disease [8–11].
The underlying molecular mechanism for development of fibrosis, cirrhosis, and portal 
hypertension has been intensively investigated over the last decades. Since the liver is formed 
by parenchymal cells (mainly hepatocytes (HEP)) and nonparenchymal cells (Kupffer cells 
(KC), hepatic stellate cells (HSC), and liver sinusoidal endothelial cells (LSEC)), both are 
involved in the development of fibrosis and cirrhosis. Nevertheless, HSC are the main cell 
type responsible for accumulation of fibrosis and increased intrahepatic vascular resistance. 
HSC are pericytes surrounding the sinusoids in the space of Disse. HSC are quiescent but 
became activated upon various stimuli and transform to myofibroblasts [12]. This activation 
process is a complex interplay between parenchymal and nonparenchymal cells and trig-
gered via inflammatory processes [13]. For instance, deleterious agents (alcohol, LPS) have 
direct hepatotoxic effects to hepatocytes and trigger the production of reactive oxygen species 
(ROS). The release of ROS, DNA, and damage-associated molecular pattern (DAMP) leading 
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to activation of KC and innate immune system followed by subsequent production of pro-
inflammatory cytokines such as TNF-α and IL-6 as well as pro-fibrotic factors [14–16]. Also, 
alcohol consumption increases permeability of the gut resulting in increased levels of portal 
endotoxins (LPS) with consecutive activation of KC resulting in liver injury and inflammation 
[17, 18]. Furthermore, inflammation triggers the classical complement pathway activation via 
C1q [19], followed by production of pro-inflammatory cytokines, and inhibits components of 
innate immune system. As a consequence of these induced inflammatory processes, activated 
KC stimulate HSC subsequently leading to fibrosis [20]. This stimulation can result directly 
by the deleterious agent [21] or via transforming growth factor beta (TGF-β)-dependent 
mechanisms [22] leading to secretion of TNF-α, IL-6, TIMP-1, MCP-1, collagen-I, and α-SMA 
[23–25] and finally collagen deposition.
As mentioned above, pro-inflammatory factors (TNF-α, IL-1β, IL-6) are also involved in the 
activation of HSC. In this regard, activation of the transcription factor nuclear factor-κB (NF-
κB) and subsequent overexpression of pro-inflammatory cytokines are important pathways. 
NF-κB, thereby, is activated by growth factors, cytokines, bacterial and viral factors, and ROS 
and regulates by itself pro-inflammatory cytokines (like COX-2 or IL-6) [26, 27].
Beside the production of collagen and accumulation of fibrotic tissue, HSC are involved in 
increased intrahepatic vascular resistance not only via structural changes. Transformation of 
HSC to myofibroblasts was accompanied by stimulation of rho kinase leading to activation of 
contractile filaments of HSC and subsequently vasoconstriction of sinusoids [28].
Another key player in the development of fibrosis comprises LSEC. They form the first line 
of defense protecting the liver from injury. Inflammation by LPS or ROS resulted in dysfunc-
tion of LSEC [29] indicated by disturbed sinusoidal microcirculation, defenestration, hypoxia, 
and pathological angiogenesis [30]. In contrast, both direct deterioration of LSEC and vaso-
constriction of HSC result in impaired release of vasodilators from LSEC leading to a vicious 
circle of disease. In this regard, disturbed regulation of NO production in cirrhosis depends 
on activity of endothelial NO synthase (eNOS) and increased degradation due to phospho-
diesterases, that is, PDE-5 [31]. Although eNOS expression is upregulated in sinusoidal area 
in cirrhosis, eNOS activity has been shown to be reduced by caveolin-eNOS binding [32] and 
was diminished by several post-translational modifications of the endothelial NO synthase 
(eNOS) [9]. In contrast, in splanchnic circulation, eNOS is upregulated [9] with increased 
enzyme activity in portal hypertension and regulated by phosphorylation of protein kinase B 
(Akt) [33]. Beside upregulation of eNOS, production of NO is also related to induction of the 
inducible form of the NO synthase, iNOS. iNOS is mainly stimulated by the presence of endo-
toxin and pro-inflammatory cytokines, all of whom occur in development of cirrhosis [34]. 
Indeed, recent study showed stimulation of iNOS rather than eNOS in splanchnic circulation 
by LPS, indicating an important role of iNOS in portal hypertension after bacterial transloca-
tion to mesenteric vessels [35]. Finally, all these alterations result in a hyperdynamic circula-
tion with elevated blood flow to portal vein and further increase of portal pressure [8–10].
In conclusion, cirrhosis demonstrates the end stage of liver disease with disturbed liver archi-
tecture and impaired liver function. Generation of ROS and stimulation of various inflamma-
tory pathways are critical steps in activation of HSC as the main driver for fibrosis. Despite 
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these findings, the use of antioxidants (vitamin E, N-acetylcysteine, coenzyme Q, and others) 
in patients with alcoholic liver disease has failed to show an efficacy in improving disease 
conditions [36–38].
3. Glyoxalase system and R(AGE)
An important role in regulation and formation of ROS and oxidative stress comprises the 
glyoxalase system. This enzymatic system was first discovered in 1913 [39] and constitutes 
two cytosolic enzymes, glyoxalase-I (Glo-I, EC 4.4.1.5) and glyoxalase-II (Glo-II, EC 3.1.2.6.). 
Glo-I is responsible for the catalytic conversion of α-oxo aldehydes, for instance, methylgly-
oxal (MGO), into the hemithioacetal S-D-Lactoylglutathione using L-glutathione (GSH) as a 
cofactor. Further substrates of Glo-I are hydroxypyruvaldehyde, hydroxypyruvate aldehyde 
phosphate, glyoxal, phenylglyoxal, 4,5-dioxovalerate, alkyl and arylglyoxales [40–43]. Glo-II 
hydrolyzes the reaction of S-D-Lactoylglutathione to H
2
O and D-lactate with regeneration of 
GSH (Figure 1). Thereby, Glo-I demonstrates the rate limiting step [42, 44], and Glo-II is of 
subordinate interest in inflammatory research.
MGO is the main substrate of Glo-I [45] and has been described as a reactive carbonyl com-
pound that is formed as a by-product in glycolysis [46], ketone body metabolism, and thre-
onine catabolism [47–49]. MGO leads to cell cytotoxicity in high concentrations through 
Figure 1. Glyoxalase system. Glyoxalase-I and glyoxalase-II comprise the glyoxalase system for detoxification of MGO. 
Glutathione is necessary as cofactor and is regenerated by Glo-II. Adapted from [43].
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reaction with nucleotides, phospholipids, and proteins [50, 51], resulting in the formation 
of “advanced glycation end products (AGEs)” and reactive oxygen species (ROS) via AGEs 
or non-enzymatic reaction with hydrogen peroxide [52]. In this regard, MGO has shown to 
be involved in various inflammatory processes such as diabetes, aging, renal insufficiency, 
hypertension, or cancer [60–64].
Important MGO-derived AGEs are the non-fluorescent products 5-hydro-5-methylimidazo-
lone (MG-H1) and tetrahydropyrimidine (THP) as well as the major fluorescent product, 
argpyrimidine [53, 54]. Other non-MGO-derived AGEs comprise Nε-carboxymethyllysine 
(CML), pyrraline, or pentosidine [55]. The effects of AGEs have been allocated to their 
antagonistic receptor systems. The receptor for AGEs (RAGE) mediates generation of ROS, 
inflammation, angiogenesis, and proliferation [56, 57]. In contrast, AGE receptors (AGE-Rs), 
for instance, AGE-R1, are responsible for detoxification and clearance of AGEs [58]. Upon 
binding of AGEs to RAGE, various signal transduction pathways are activated. Recent 
studies showed involvement of the extracellular signal-regulated kinase 1/2 (ERK1/2), 
phosphoinositide 3-kinase (PI3-K)/protein kinase B (AKT), Janus kinase 2 (JAK2), and Rho 
GTPases, finally resulting in activation of NF-κB and production of pro-inflammatory cyto-
kines (Figure 3) [59]. In addition, stimulation of RAGE resulted in activation of transform-
ing growth factor (TGF-β) pathway and induced vascular endothelial growth factor (VEGF) 
overexpression [57].
In the last years, structure and genomic sequence of Glo-I was intensively analyzed. Glo-I is 
a dimer and consists in mammalian of two identical subunits with a molecular mass of 43–48 
kDa [60]. Each subunit contains a zinc ion in its active center, whereas the apoenzyme remains 
catalytically inactive [45, 61]. The active center of Glo-I is localized between both monomers 
and comprises two structurally equivalent residues from each domain (Gln-33A, Glu-99A, 
His-126B, Glu-172B) and two water molecules indicating an octahedral arrangement [54, 62]. 
The protein sequence of Glo-I consists of 184 amino acids with post-translational modification 
of N-terminal Met [62].
Genomic analysis revealed three distinct phenotypes of Glo-I: GLO 1-1, GLO 1-2, and GLO 
2-2 representing homo- and heterozygous expression of GLO1 und GLO2 [63, 64]. Gene locus 
of Glo-I is determined on chromosome six between centromere and human leukocyte anti-
gen (HLA)-DR gene [65, 66]. Demographic studies showed higher distribution of GLO1 in 
Alaska and lower GLO1 allocation in southern and eastern Europe, America, Africa, and 
India [67].
Genetic sequencing identified association of distinct Glo-I phenotypes and Glo-I SNPs with 
diabetes [68], cardiovascular diseases [69], schizophrenia [70], autism [71, 72], anxiety [73], 
and cancer [74, 75]. These findings led to preliminary anti-tumor effects of Glo-I inhibition 
by siRNA or enzymatic inhibition in different cancer models [76–79]. In this regard, well-
studied Glo-I inhibitors are S-ρ-bromobenzylglutathione or S-ρ-bromobenzyl-glutathione 
cyclopentyl diester [77, 80], methotrexate [81], indomethacin [82], troglitazone [83], and 
flavonoids [84, 85] showing anti-inflammatory and anti-tumor effects. Furthermore, an 
Glo-I inducer led to improved glycemic control and vascular function in 29 obese patients 
[86].
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In a nutshell, Glo-I is responsible for detoxification of MGO and prevention of MGO-related 
formation of AGEs and ROS. Therefore, Glo-I and (R)AGE are involved in different patho-
physiological inflammatory processes.
4. Glo-I and R(AGE) in fibrosis, cirrhosis, and NAFLD/NASH
4.1. Glo-I
To date, although Glo-I revealed an important role in inflammation, data about Glo-I in chronic 
liver disease remain preliminary. In an experimental approach of CCl
4
-induced cirrhosis, Glo-I 
was analyzed in vivo and in vitro [87]. Wistar rats were treated with inhalative CCl
4
 three times 
a week to induce early cirrhosis (without ascites) after 8 weeks or advanced cirrhosis (with 
ascites) after 12 weeks. Furthermore, primary liver cells from cirrhotic and noncirrhotic livers 
were isolated via portal vein perfusion and analysis of Glo-I was performed. Glo-I could be 
detected in HEP, HSC, and LSEC with highest expression on protein and mRNA levels in HEP. 
Furthermore, Glo-I expression was reduced in early and advanced cirrhosis in both whole 
liver and primary liver cells (Figure 2A). The reduction in Glo-I expression was greater with 
increasing severity of liver disease. Interestingly, the reduction of Glo-I was accompanied by an 
increase of MGO in cirrhosis (Figure 2B). This accumulation of MGO would lead to increased 
formation of AGEs and finally augment oxidative stress with ongoing inflammation in chronic 
liver disease [87]. So far, the reduction of Glo-I with consecutive increase of MGO would pro-
vide an explanation for perpetuating liver inflammation in advanced stages of liver disease.
Furthermore, modulation of Glo-I activity with the anti-inflammatory drug ethyl pyruvate 
(EP) was performed to analyze impact of Glo-I in initiation and progression of cirrhosis. EP 
is an α-oxo-carbonic acid and ester of pyruvate. EP came in focus due to anti-inflammatory 
effects of pyruvate but low stability in aqueous solution [88]. Therefore, EP constitutes a more 
stable compound and exerts anti-inflammatory and protective effects in a lot of ROS-mediated 
models [89, 90]. Therefore, a possible molecular basis for the anti-inflammatory effects of EP 
was assumed to be the inhibition of specific Glo-I activity [91].
Since EP showed protective effects in acute liver failure [92–95] and development of fatty liver 
[96], effect of EP on activation of HSC, as it might occur in initial stadium of cirrhosis, was ana-
lyzed. Stimulation of HSC with LPS for 24 hours led to increased levels of α-SMA, indicating 
activation of HSC and production of collagen deposit. This stimulation could be abrogated 
by modulation of Glo-I activity by means of EP (Figure 2c). Underlying mechanisms involve 
stimulation of Nrf2 as well as reduction of NF-κB and ERK/pERK by EP. Additional in vivo 
experiments revealed reduced collagen deposit in Wistar rats that were treated with CCl
4
 for 
12 weeks and i.p. EP [87]. Furthermore, EP-treated rats revealed significantly less Sirius red 
staining and consequently less fibrosis compared with controls receiving saline (Figure 2D).
Indeed, anti-inflammatory treatment of several diseases with EP might be a promising future 
clinical approach. However, EP was analyzed in a clinical trial (phase-II multicenter double-
blind placebo-controlled study) in high-risk patients undergoing cardiac surgery with car-
diopulmonary bypass. This trial was performed in 13 US hospitals including patients with 
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a Parsonnet risk score > 15 undergoing coronary artery bypass graft and/or cardiac valvu-
lar surgery with cardiopulmonary bypass. 102 subjects received either placebo (53) or 7.500 
mg (90 mg/kg) EP (49) intravenously followed by five more doses every 6 hours. The pri-
mary endpoint was a combination of death, prolonged mechanical ventilation, renal failure, 
or need of vasoconstrictors. No statistically significant differences were observed between 
groups with regard to clinical parameters or markers of systemic inflammation [97]. Despite 
these disappointing results in the first clinical trial, it should be kept in mind that underlying 
molecular mechanisms in cardiac surgery with cardiopulmonary bypass are complex and 
at least partly different from ROS models showing protective effects of EP. Another clinical 
study design, for example, liver fibrosis, pancreatitis, septic shock, might be more promising 
for this interesting agent.
In summary, targeting Glo-I with EP in cirrhosis revealed an innovative therapeutic target. 
Nevertheless, further research needs to confirm the aforementioned results in further animal 
experiments and clinical trials.
4.2. AGEs
In contrast to straightforward evidence of Glo-I in chronic liver disease, several groups ana-
lyzed AGEs in liver fibrosis, cirrhosis, and NASH. In cirrhotic patients, limited amount of 
methylglyoxal-modified proteins were found to be elevated compared to controls [98]. 
Figure 2. Glyoxalase-I in CCl
4
-induced cirrhosis. (A), Glo-I expression was reduced in early (8 week CCl
4
-treatment) 
and advanced (12 week CCl
4
-treatment) cirrhosis in Western blot. Wistar rats were treated three times per week 
with inhalative CCl
4
 for induction of cirrhosis. (B), MGO levels were significantly elevated in cirrhosis, indicated by 
ELISA-analysis. (C), treatment of stellate cells (HSC) for 24 hours with LPS revealed increased production of α-SMA. 
Cotreatment with Glo-I modulator ethyl pyruvate (EP) abolished the LPS-induced effects. (D), Wistar rats were treated 
with CCl
4
 and i.p. EP or saline from week 8 to 12. Sirius red staining indicated significantly less fibrosis in EP-treated 
animals. * p < 0.05, ** p < 0.01, *** p < 0.001. Adapted from [87].
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Another study revealed increased levels of CML-AGEs in blood plasma of cirrhotic patients. 
Also, CML levels correlated with severity of disease [99]. Additional studies confirmed the 
observations of increased CML levels in fibrosis and cirrhosis [100, 101]. These clinical find-
ings were supported by laboratory analysis: in vitro treatment of HSC with AGEs resulted in 
enhanced production of oxidative stress providing evidence of AGEs-involvement in fibrosis 
[102]. Conversely, oxidative stress was found to elevate levels of CML in rats [103] and incu-
bation of HSC with AGEs led to elevation of α-SMA, TGF-β, and collagen-I [104]. In addition, 
treatment of rat hepatocyte cultures with AGEs reduced cell viability [105]. In an interesting 
translational study, CML-AGEs were positively correlated with liver stiffness in patients with 
chronic hepatitis C. In vitro data showed in this study enhanced cell proliferation of HSC 
treated with BSA-AGEs (CML) and increased production of α-SMA. In contrast, in another 
study, intraperitoneal administration of AGE-rat serum albumin (CML) revealed increased 
levels of α-SMA and fibrosis in a model of bile duct ligation [106]. Furthermore, AGEs were 
found to induce autophagy which subsequently contributes to the fibrosis in patients with 
chronic hepatitis C [107]. The finding that AGEs were elevated in fibrosis and treatment with 
AGEs-induced fibrosis led to an interventional approach targeting AGEs to prevent induction 
of chronic liver disease. Indeed, inhibition of CML resulted in attenuation of CML-induced 
levels of α-SMA and ROS in HSC [108].
Another model to study fibrosis belongs to metabolic liver diseases: induction of NASH by 
means of methionine choline deficient diet (MCD). Therefore, hepatic steatosis induced by 
MCD showed accumulation of CML, and CML was associated with grade of hepatic inflam-
mation and gene expression of inflammatory markers (PAI-1, IL-8, and CRP) [109]. AGEs 
have also been shown to be involved in etiology of insulin resistance and diabetes [110], and 
rats fed with a diet rich in AGEs showed elevated oxidative stress and hepatic inflammation 
leading to NASH [111]. In addition, high dietary AGEs increased hepatic AGEs levels and 
induced liver injury, inflammation, and liver fibrosis via oxidative stress in activated HSC 
[112]. Another interesting study investigated the underlying mechanism of AGEs-crosstalk 
in NASH. AGEs induced NOX2 leading to downregulation of Sirt1/Timp3 and finally result-
ing in activation of TNF-α converting enzyme and inflammation. These pro-inflammatory 
cascades finally led to NASH and fibrosis [113]. Interventional studies on AGEs reduction 
in NASH also revealed promising results. The flavonoid curcumin eliminated the inflam-
matory effects of AGEs in HSC by interrupting leptin signaling and activating transcription 
factor Nrf2, which led to the elevation of cellular glutathione levels and the attenuation of 
oxidative stress [114]. In addition, curcumin decreased activation and proliferation of HSC by 
AGEs and induced gene expression of AGE-clearing receptor AGE-R1 [115]. The use of the 
LDL-lowering drug atorvastatin [116] or combination therapy of telmisartan and nateglinide 
[117] also decreased levels of AGEs in patients with NASH and dyslipidemia, leading to 
improvement of steatosis, nonalcoholic fatty liver disease activity score, and amelioration of 
insulin resistance. Another study evaluated effects of aqueous extracts from Solanum nigrum 
(AESN). AESN could reduce the AGE-induced expression of collagen-II, MMP-2, and α-SMA 
in HSC. Also, AESN improved insulin resistance and hyperinsulinemia and downregulated 
lipogenesis, finally preventing fibrosis [118].
Having the auspicious and conclusive effects of AGEs-lowering drugs in fibrosis in mind, it 
should be noted that mainly CML-AGEs were investigated. Therefore, it should be  considered 
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that CML-AGEs are rarely produced via reaction of MGO but are rather formed in lipoxida-
tion and glycoxidation independent of MGO [119].
4.3. RAGE
The pattern recognition receptor RAGE belongs to the immunoglobulin superfamily with a 
molecular mass of 47–55 kDa. RAGE expression is stimulated under inflammatory conditions 
such as diabetes, cardiovascular diseases, or cancer [120]. RAGE has been shown to be acti-
vated by MGO- and non-MGO-derived AGEs as well as multiple ligands. Binding to RAGE 
results in activation of transcription factors, such as NF-κB [121], leading to the release of 
pro-inflammatory cytokines.
Indeed, several studies revealed participation of RAGE in fibrosis: Upon stimulation with 
AGE-rat serum albumin containing mainly CML, levels of RAGE, α-SMA, hydroxypro-
line, and Sirius red were elevated in a fibrosis model of bile duct ligation (BDL) [106, 122]. 
Interestingly, RAGE was found to be predominantly expressed in HSC. RAGE was stimulated 
in HSC during transformation to myofibroblasts, and RAGE was colocalized with α-SMA and 
induced by TGF-β. In addition, RAGE was expressed in filopodial membranes of myofibro-
blasts suggesting a role of RAGE in spreading and migration of activated HSC in fibrogenesis 
[123]. Further analysis provided evidence for crosstalk of RAGE and TGF-β: AGEs-induced 
upregulation of RAGE induced TGF-β, TNF-α, and IL-8. Interestingly, RAGE also stimulated 
anti-inflammatory cytokines IL-2 and IL-4 indicating a negative feedback mechanism and 
inhibitory crosstalk between TGF-β and RAGE [124]. In the next step, effect of RAGE inhi-
bition on inflammation and fibrosis was discovered. First, curcumin was found to reduce, 
besides its AGEs-lowering effects, the gene expression of RAGE via elevation of PPAR-γ [125]. 
Furthermore, RAGE expression was diminished by means of RAGE siRNA in primary rat 
HSC resulting in downregulation of IL-6, TNF-α, and TGF-β [126]. In a following in vivo 
study, effects of repetitive RAGE siRNA in an olive oil model of fibrosis were analyzed. RAGE 
siRNA was injected twice weekly in the tail vein of Sprague-Dawley rats. After 6 weeks, 
reduced expressions of RAGE, TNF-α, IL-6, extracellular matrix, hyaluronic acid, and procol-
lagen III were found. Also, activation of HSC and NF-κB was reduced in siRNA-treated ani-
mals attenuating the initiation and progression of fibrosis [127]. Additional studies revealed 
protective effects of anti-RAGE antibodies in BDL-induced acute liver injury [128, 129].
Growing evidence for implication of RAGE in fibrosis was found in NASH. Methionine cho-
line deficient (MCD) diet caused steatosis and increased RAGE, inflammation, and fibrosis 
[112]. Recently, fatty acids stimulated CML accumulation and subsequently elicited RAGE 
induction [109]. Another group found upregulation of RAGE in the liver of aged mice with 
consecutive elevated oxidative stress shown by analysis of malondialdehyde. Blocking of 
RAGE by anti-RAGE-antibody revealed in this study prolonged survival of animals [130].
In a nutshell, various studies confirmed implication of Glo-I and (R)AGE in inflammatory 
liver disease and fibrosis. Especially targeting Glo-I in cirrhosis highlighted the meaning of 
MGO-induced liver damage and offers new therapeutic opportunities. Nevertheless, further 
research in this topic will uncover the exact role of Glo-I in chronic liver disease and possible 
translation to clinical approach (see Figure 3).




Figure 3. Impact of Glo-I and (R)AGE in cirrhosis. MGO reacts with proteins, nucleotides, and lipids leading to formation 
of AGEs. AGEs bind to RAGE and activate several signal pathways (including MAPK (ERK1/2, p38, JNK), PI3-K/AKT, 
and JAK2/STAT1), finally leading to activation of NF-κB. In a consequence, the induced production of TGF-β and pro-
inflammatory cytokines activate quiescent stellate cells. HSC transform to myofibroblasts and produce pro-fibrotic 
factors and collagen. The collagen deposition in the liver will lead to fibrosis and finally cirrhosis. Reduction of Glo-I will 
perpetuate both, initiation and progression of cirrhosis due to increase of MGO and a vicious circle of disease. MGO: 
methylglyoxal, AGEs: advanced glycation end products, RAGE: receptor for advanced glycation end products, Glo-I: 
glyoxalase-I, HSC: hepatic stellate cells, MAPK: mitogen-activated protein kinase, PI3-K: phosphoinositide 3-kinase, 
AKT: protein kinase B, JAK2: Janus kinase 2, STAT1: signal transducer and activator of transcription-1, JNK: c-Jun 
N-terminal kinase, and NF-κB: nuclear factor-κB.
AGEs advanced glycation end products
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